So when a meta-analysis finds GLP-1 patients losing 3035% of total weight as lean mass, the question isn't whether GLP-1s are uniquely catabolic
Skip to main content An official website of the United States government Espaol Menu Search Search About Cancer Cancer Types Research Grants & Training News & Events About NCI Home Publications NCI Dictionaries NCI Dictionary of Genetics Terms Publications Patient Education Publications PDQ Fact Sheets NCI Dictionaries Dictionary of Cancer Terms Drug Dictionary Dictionary of Genetics Terms Blogs and Newsletters Health Communications Publications Reports You need to enable JavaScript to run this app.
These results were achieved when the medication was used along with a reduced-calorie diet and regular physical activity, which are important parts of the treatment
Semaglutide, liraglutide, and tirzepatide are all FDA-approved medications for weight loss
Jingye Zhou, Eccogene CEO Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline Eccogene, a clinical-stage biotech whose oral GLP-1 drug forms the backbone of AstraZenecas obesity pipeline, is planning an initial public offering on the Hong Kong Sign up to read this article for free
